Pathway Medical Partners, LLC
$66.0K 33 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Spinevision SAS
Spinevision SAS reported $65,951.00 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 12 transactions.
- $66.0K
- All-tracks total
- 12
- Transactions
- 12
- Recipients
- −$91.4K
- General Payments vs PY2023
Spinevision SAS reported $65,951.00 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #1282 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $65,951.00, averaging $5.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer spinevision-sas Spinevision SAS
$66.0K · #1282/1,925 · 0.0% industry · PY2024
- TOT $66.0K
- RANK #1282
- SHARE 0.0%
- TXN 12
- RCP 12
- CAT 4
- GEN $66.0K
- ΔGEN −$91.4K
- TOP1 73.7%
- PY 2024
Volume peers
Nearest volume peer: Pathway Medical Partners, LLC ($66.0K)
Spinevision SAS sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Spinevision SAS's CMS-reported General Payments decreased by $91.4K (−58.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPINEVISION SASPY2023: SPINEVISION SASPY2024: Spinevision SAS. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $157,331.00
- PY2024
- $65,951.00
What the Data Shows for Spinevision SAS
$65,951.00: that is what Spinevision SAS reported in payments to 12 physicians and teaching hospitals during Program Year 2024, spread across 12 transactions ($5.5K per transaction, $5.5K per recipient). The company sits at rank #1282 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $48.4K, accounting for 73.4% of this company's General Payments and 1 transactions.
General Payment Breakdown by Type
Across 4 types of general payments, Spinevision SAS's largest category was "Royalty or License" at $48.4K - 73.4% of General Payments.
Spinevision SAS reports 4 general-payment categories - the top three are Royalty or License (73.4%), Travel and Lodging (22.0%), and Consulting Fee (3.0%). The remaining 1 category make up 1.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Spinevision SAS divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $48.4K | 1 | 73.4% |
| Travel and Lodging | $14.5K | 2 | 22.0% |
| Consulting Fee | $2.0K | 1 | 3.0% |
| Food and Beverage | $1.0K | 8 | 1.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $65,641.00 (99.5%) of $65,951.00 in this company's General Payments records across 8 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Spinevision SAS
The five named recipients with the highest reported General Payments from this company
- 1
Gary Colon
$48,608.00 across 3 reported transactions
- 2
Pawel Jankowski
$9,966.00 across 2 reported transactions
- 3
Vivek Mehta
$6,730.00 across 2 reported transactions
- 4
Rebecca Kuo
$217.00 across 1 reported transactions
- 5
Hamad Farhat
$120.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Spinevision SAS's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Spinevision SAS.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Spinevision SAS.
Showing 6 of 1,924 companies with CMS-reported payment data.
Cambridge Interventional LLC
$66.1K 36 recipients
Compare payment profiles
Valinor Pharma, LLC
$65.8K 4,160 recipients
Compare payment profiles
SS White Burs, Inc.
$65.6K 105 recipients
Compare payment profiles
Swan Valley Medical Incorporated
$65.3K 7 recipients
Compare payment profiles
Momentis Surgical Inc.
$66.7K 21 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.